Amylin receptors
The compound is designed to selectively activate amylin receptors involved in satiety and metabolic signaling.
P—25 • Investigational clinical profile
Eloralintide(Also known as LY3841136)
A concise educational overview of an investigational long-acting amylin receptor agonist studied in obesity and metabolic research.
Name
Eloralintide
Also known as LY3841136
- Scientific classification
- Synthetic, long-acting selective amylin receptor agonist
- Library family
- Metabolic
- Research status
- Investigational; Phase 1 findings are published and additional clinical studies are ongoing
- Regulatory status
- No FDA-approved eloralintide product or indication
Compound overview
An investigational peptide designed to selectively engage amylin-receptor signaling.
Amylin is a peptide hormone co-secreted with insulin and involved in satiety, gastric, and metabolic signaling. Eloralintide was engineered as a long-acting compound that selectively activates amylin receptors.
Published evidence remains early. A randomized Phase 1 study examined safety, tolerability, pharmacokinetics, pharmacodynamics, and body-weight outcomes, while additional clinical research is ongoing.
Mechanism under study
Selective, long-acting amylin-receptor signaling
Eloralintide is being studied for sustained engagement of amylin receptors and the downstream metabolic responses associated with that pathway.
Long-acting exposure
Its molecular design is intended to support extended exposure, which is evaluated through pharmacokinetic studies.
Metabolic endpoints
Clinical research measures body weight, tolerability, and other metabolic outcomes under controlled study conditions.
Early clinical signals require confirmation in larger and longer trials. They do not establish an approved treatment or the equivalence of research-market materials.
Current research areas
Questions under investigation
- Amylin-receptor selectivity
- Pharmacokinetics and pharmacodynamics
- Obesity and body-weight outcomes
- Use alongside incretin therapy in controlled trials
- Longer-term safety and tolerability
Evidence summary
Early clinical research findings
- Phase 1 evidence: A randomized controlled study evaluated safety, tolerability, exposure, and pharmacodynamic outcomes.
- Pharmacokinetics: Published findings described dose-related exposure across the studied regimens.
- Body-weight research: The Phase 1 study included 12-week body-weight outcomes as part of its clinical evaluation.
- Ongoing research: A registered study is evaluating eloralintide in participants with persistent obesity treated with a weekly incretin.
Eloralintide remains investigational. Published Phase 1 findings and trial registration do not establish broad clinical effectiveness, long-term safety, or regulatory approval.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, dosing information, or instructions for eloralintide use. Eloralintide is investigational, and published clinical material should not be assumed to match the identity, purity, or properties of research-market products.
Key scientific references